Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 82 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Pectasides, Dimitrios  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Pentheroudakis, G., Kalogeras K. T., Wirtz R. M., Grimani I., Zografos G., Gogas H., et al. (2009).  Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.. Breast Cancer Res Treat. 116(1), 131-43.
Zarkavelis, G., Kotoula V., Kolliou G-A., Papadopoulou K., Tikas I., Karavasilis V., et al. (2019).  Genetic mapping of pancreatic cancer by targeted next-generation sequencing e. ESMO Open. 4(5), e000525.
Purrington, K. S., Slager S., Eccles D., Yannoukakos D., Fasching P. A., Miron P., et al. (2014).  Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.. Carcinogenesis. 35(5), 1012-9.
Chatzopoulos, K., Kotoula V., Koliou G-A., Giannoulatou E., Papadopoulou K., Karavasilis V., et al. (2020).  Genotype - phenotype associations in colorectal adenocarcinomas and their matched metastases.. Hum Pathol.
Linardou, H., Kotoula V., Kouvatseas G., Mountzios G., Karavasilis V., Samantas E., et al. (2019).  Genotyping and Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment.. Cancer Genomics Proteomics. 16(6), 531-541.
I
Fountzilas, E., Kotoula V., Angouridakis N., Karasmanis I., Wirtz R. M., Eleftheraki A. G., et al. (2013).  Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer.. PLoS One. 8(8), e70429.
Pentheroudakis, G., Raptou G., Kotoula V., Wirtz R. M., Vrettou E., Karavasilis V., et al. (2015).  Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.. PLoS One. 10(5), e0124612.
Kourea, H. P., Kotoula V., Koutras A., Alexopoulou Z., Papaspirou I., Skarlos D. V., et al. (2015).  Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.. Histol Histopathol. 30(9), 1129-41.
Razis, E., Kalogeras K. T., Kotoula V., Eleftheraki A. G., Nikitas N., Kronenwett R., et al. (2012).  Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.. Clin Breast Cancer. 12(3), 183-93.
Vassilakopoulou, M., Togun T., Dafni U., Cheng H., Bordeaux J., Neumeister V. M., et al. (2014).  In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.. PLoS One. 9(6), e99131.
Lakis, S., Dimoudis S., Kotoula V., Alexopoulou Z., Kostopoulos I., Koletsa T., et al. (2016).  Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.. Anticancer Res. 36(5), 2365-78.
Kalofonos, H. P., Papakostas P., Makatsoris T., Papamichael D., Vourli G., Xanthakis I., et al. (2010).  Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.. Anticancer Res. 30(10), 4325-33.
Fountzilas, G., Kotoula V., Pectasides D., Kouvatseas G., Timotheadou E., Bobos M., et al. (2013).  Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.. PLoS One. 8(7), e69256.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.